Fighting Fire with Fire: Is it Time to Use Probiotics to Manage Pathogenic Bacterial Diseases?
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Probiotics, when considered in clinical practice, have traditionally been used for prophylaxis; however, there is growing data suggesting treatment benefits in numerous disease states. In this review, we focus on probiotics as treatment for and prevention of several acute and chronic infectious processes including Helicobacter pylori, Clostridium difficile, necrotizing enterocolitis, ventilator-associated pneumonia, vancomycin-resistant enterococci, and nonalcoholic fatty liver disease. It is inaccurate to generalize findings observed in a single probiotic species to all probiotics. This reasoning is due to the variability of colonizing abilities of native intestinal floras, probiotic or otherwise, secondary to different combinations, doses, and duration of treatments. Given these limitations, multiple animal and human studies have shown anti-inflammatory and selective antimicrobial effects of specific probiotics. Some studies suggest a role for probiotics as supplemental treatment, in combination with antibiotics, for the aforementioned disease processes. It is apparent from this review that the efficacy of probiotics is widely variable and multifaceted. More focused clinical and basic science research is necessary to better understand the treatment potential of various probiotics.
- Fuller R. Probiotics in human medicine. Ann Med. 1990;22:37–41. CrossRef
- Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a north central cancer treatment group trial. Cancer. 2005;104(1):176–82. CrossRef
- Bassler W. Civ. no. 99–5782 (WGB). US District Court for the District of New Jersey. 2004.
- Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347(15):1175–86. CrossRef
- Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American college of gastroenterology guideline on the management of helicobacter pylori infection. Am J Gastroenterol. 2007;102(8):1808–25. CrossRef
- Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53. CrossRef
- Michetti P, Dorta G, Wiesel PH, et al. Effect of whey-based culture supernatant of lactobacillus acidophilus (johnsonii) La1 on helicobacter pylori infection in humans. Digestion. 1999;60(3):203–9. CrossRef
- Mukai T, Tomoko A, Sato E, et al. Inhibition of binding of heliobacter pylori to the glycolipid receptors by probiotic lactobacillus reuteri. Immunol Med Microbiol. 2001;32:105–10. CrossRef
- Lorca GL, Wadstrom T, Valdez GF, Ljungh A. Lactobacillus acidophilus autolysins inhibit helicobacter pylori in vitro. Curr Microbiol. 2001;42(1):39–44. CrossRef
- Collado MC, Gonzalez A, Gonzalez R, Hernandez M, Ferrus MA, Sanz Y. Antimicrobial peptides are among the antagonistic metabolites produced by bifidobacterium against helicobacter pylori. Int J Antimicrob Agents. 2005;25(5):385–91. CrossRef
- Tong JL, Ran ZH, Shen J, Zhang CX, Xiao SD. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155–68. CrossRef
- Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of saccharomyces boulardii supplementation on helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069–79. CrossRef
- Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S. Efficacy and safety of saccharomyces boulardii in the 14-day triple anti-helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309–16. CrossRef
- Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-helicobacter pylori therapy-related side effects: a parallel group, triple blind, placebo-controlled study. Am J Gastroenterol. 2002;97(11):2744–9. CrossRef
- Duman DG, Bor S, Ozutemiz O, et al. Efficacy and safety of saccharomyces boulardii in prevention of antibiotic-associated diarrhoea due to helicobacterpylori eradication. Eur J Gastroenterol Hepatol. 2005;17(12):1357–61. CrossRef
- Hurduc V, Plesca D, Dragomir D, Sajin M, Vandenplas Y. A randomized, open trial evaluating the effect of saccharomyces boulardii on the eradication rate of helicobacter pylori infection in children. Acta Paediatr. 2009;98(1):127–31. CrossRef
- Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of helicobacter pylori. Helicobacter. 2010;15(3):206–13. CrossRef
- Kelesidis T, Pothoulakis C. Efficacy and safety of the probiotic saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therap Adv Gastroenterol. 2012;5(2):111–25. CrossRef
- Safdar N, Maki DG. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant staphylococcus aureus, enterococcus, gram-negative bacilli, clostridium difficile, and candida. Ann Intern Med. 2002;136(11):834–44.
- Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of clostridium difficile treatments: a systematic review. Ann Intern Med. 2011;155(12):839–47.
- McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of saccharomyces boulardii in combination with standard antibiotics for clostridium difficile disease. JAMA. 1994;271(24):1913–8. CrossRef
- Surawicz C, McFarland L, Greenberg R. The search for a better treatment for recurrent clostridium difficile disease: Use of high-dose vancomycin combine with saccharomyces boulardii. Clin Infect Dis. 2000;31:1012–1017.
- Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent clostridium difficile disease. J Med Microbiol. 2005;54(Pt 9):905–6. CrossRef
- McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of clostridium difficile disease. Am J Gastroenterol. 2006;101(4):812–22. CrossRef
- Hickson M, D'Souza AL, Muthu N, et al. Use of probiotic lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ. 2007;335(7610):80. CrossRef
- Pillai A, Nelson R. Probiotics for treatment of clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev. 2008;(1)(1):CD004611.
- Thilo E, Rosenberg A. The newborn infant. Current Diagnosis & Treatment (20th Edition): Pediatrics. 2011.
- Frost BL, Caplan MS. Probiotics and prevention of neonatal necrotizing enterocolitis. Curr Opin Pediatr. 2011;23(2):151–5. CrossRef
- Bin-Nun A, Bromiker R, Wilschanski M, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005;147(2):192–6. CrossRef
- Lin HC, Hsu CH, Chen HL, et al. Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: a multicenter, randomized, controlled trial. Pediatrics. 2008;122(4):693–700. CrossRef
- Deshpande G, Rao S, Patole S, Bulsara M. Updated meta-analysis of probiotics for preventing necrotizing enterocolitis in preterm neonates. Pediatrics. 2010;125(5):921–30. CrossRef
- Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;(3)(3):CD005496.
- Morrow LE, Kollef MH, Casale TB. Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med. 2010;182(8):1058–64. CrossRef
- Sachdev G, Napolitano LM. Postoperative pulmonary complications: Pneumonia and acute respiratory failure. Surg Clin North Am. 2012;92(2):321–44, ix.
- Napolitano LM. Perspectives in surgical infections: what does the future hold? Surg Infect (Larchmt). 2010;11(2):111–23. CrossRef
- Klarin B, Molin G, Jeppsson B, Larsson A. Use of the probiotic lactobacillus plantarum 299 to reduce pathogenic bacteria in the oropharynx of intubated patients: a randomised controlled open pilot study. Crit Care. 2008;12(6):R136. CrossRef
- Siempos II, Ntaidou TK, Falagas ME. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010;38(3):954–62. CrossRef
- Schultz MJ, Haas LE. Antibiotics or probiotics as preventive measures against ventilator-associated pneumonia: a literature review. Crit Care. 2011;15(1):R18. CrossRef
- Vidal M, Forestier C, Charbonnel N, Henard S, Rabaud C, Lesens O. Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol. 2010;48(7):2595–8. CrossRef
- Kim AS. Using the good to beat out the bad: probiotics for eliminating vancomycin-resistant enterococci colonization. J Clin Gastroenterol. 2011;45(10):844–5. CrossRef
- Mlynarczyk A, Szymanek-Majchrzak K, Kosykowska E, et al. The dominant sequence types of vancomycin-resistant enterococcus faecium among transplantation ward patients. Transplant Proc. 2011;43(8):3132–4. CrossRef
- Manley KJ, Fraenkel MB, Mayall BC, Power DA. Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust. 2007;186(9):454–7.
- Szachta P, Ignys I, Cichy W. An evaluation of the ability of the probiotic strain lactobacillus rhamnosus GG to eliminate the gastrointestinal carrier state of vancomycin-resistant enterococci in colonized children. J Clin Gastroenterol. 2011;45(10):872–7. CrossRef
- Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the united states in 1999–2002. Am J Gastroenterol. 2006;101(1):76–82. CrossRef
- Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122(6):1649–57. CrossRef
- Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology. 2003;37(2):343–50. CrossRef
- Cani PD, Delzenne NM. The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des. 2009;15(13):1546–58. CrossRef
- Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005;39(6):540–3. CrossRef
- Lirussi F, Mastropasqua E, Orando S. No evidence to support or refute probiotics for patients with non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database of Systematic Reviews. 2007;CD005165.
- Fighting Fire with Fire: Is it Time to Use Probiotics to Manage Pathogenic Bacterial Diseases?
Current Gastroenterology Reports
Volume 14, Issue 4 , pp 343-348
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Industry Sectors